In Flemingsberg, we cure diseases that were previously considered incurable

Earlier this year we hosted the most meaningful ATMP event of the spring, in collaboration with Miltenyi Biotec and the Karolinska ATMP Center, Karolinska University Hospital and Karolinska Institutet. We gathered over 120 participants, all sharing a vision of creating momentum to accelerate access to ATMPs in the Nordics.

”It’s fantastic, it’s a great opportunity to learn more about what’s going on at Karolinska and for the whole ATMP environment. From the Pre GMP to the manufacturing, to then the clinical trials that they offer here, and I think that’s one of the things that are really unique about the whole Flemingsberg ATMP ecosystem” – Jonathan Clarke, Development Manager at SmartCella.

During the event we launched ATMP Flemingsberg, a platform that encapsulates all the expertise within ATMP in Flemingsberg, from research to clinical implementation.

”We have everything in Flemingsberg and you can see that because they come here from Uppsala and other parts of the world to manufacture their products and do their treatments here” – Ewa Ellis, ATMP coordinator at Karolinska University Hospital.

The seminar shed light on Pre-GMP and GMP, as well as how to advance one’s process to the next level and how Vecura can assist in scaling up. Additionally, Stefan Mielke, an expert in the field, discussed equal access and emphasized the importance of collaborative efforts to make therapies more accessible to patients. Di Yu from Elicera Therapeutics also shared their journey, which began at Vecura in Flemingsberg.

“Clinical trials are very important because they bring innovation to our patients. For those of you who don’t know what CAR-T cells are, they are like glasses for T-cells, so that they can see tumor cells.” – Stephan Mielke, Professor and Scientific Director of the Cancer Center.

Watch our film below, summarizing our successful event. Together, we can accelerate access to ATMPs in the Nordics.

Visit atmpflemingsberg.se

*ATMP (Advanced Therapy Medicinal Products) också kallade Avancerade terapiläkemedel är baserade på celler, vävnader eller gener och delas in i tre huvudkategorier: somatiska cellterapier, genterapier och vävnadstekniska produkter.

OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg

Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on the Flemingsberg Campus. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.

Drivhuset Stockholm – Where Future Entrepreneurs Take Their First Steps

Imagine a place where young ideas are free to grow, where passion meets ambition, and where the entrepreneurs of tomorrow take their first steps toward greatness. That’s exactly what Drivhuset Stockholm offers – a springboard for the next generation of entrepreneurs. Located on Campus Flemingsberg, we support students every day as they bring their ideas to life and build the skills needed to create real change. Our mission? To provide them with a safe, inspiring environment where they can test and develop their business ideas for real.

Hitchhiker’s Guide to Startup Success: Mastering the Art of the Perfect Pitch

Earlier this fall, we launched the first event in our seminar series, Hitchhiker’s Guide to Startup Success, which we are organizing together with Miltenyi Biotec. The inaugural session featured an inspiring workshop led by pitch expert and coach Malcolm Larri. The event gathered innovators and entrepreneurs in the Life Sciences sector, with a particular focus on Advanced Therapy Medicinal Products (ATMP)—a rapidly growing field with tremendous potential to revolutionize healthcare.

12 Next